In a study 52.1% of patients receiving ferric citrate attained a 1.0 g/dL or greater increase in hemoglobin compared with just 19.1% receiving placebo.
Purgative products introduce 10 times the normal daily amount of phosphorus into the body.
Younger patients are less likely to respond to treatment with sucroferric oxyhydroxide or sevelamer.
Study implicates amlodipine, lisinopril, clonidine, acetaminophen, and omeprazole.
The percentage of patients with serum phosphorus levels of 5.5 mg/dL and below more than doubled to 37.8% after 6 months of treatment with sucroferric oxyhydroxide.
Patients also needed fewer phosphate binder pills over time.
The risk of end-stage renal disease was 83% higher for those who drank more than 7 glasses of diet soft drinks weekly.
It can sharply lower serum phosphorus levels and reduce dependence on phosphate binders.
In a study, 69.7% of intervention patients attained serum phosphorus levels below 5.5 mg/dL, compared with just 18.5% of control patients.
A low protein, low phosphorus diet plays an important role in the nutritional management of patients transitioning to once-weekly incremental hemodialysis.
Hyperphosphatemia was associated with more than double the risk of death from any cause.
Patients reduced dietary phosphorus without compromising protein intake.
The USDA Standard Nutrient Reference Database, for example, listed phosphorus amounts for just 5 of 46 beverages.
For each 1 mmol/L increase in serum phosphorus, the odds of left ventricular hypertrophy more than doubled.
Calcium-based binders, however, are associated with greater odds of all-cause mortality versus sevelamer.
In a study, 61% of hemodialysis patients reported accidentally forgetting to take their medication or otherwise skipping doses unintentionally.
Over 33 months, the 25-hydroxyvitamin D level of ergocalciferol recipients increased significantly from 15.14 to 37.32 ng/mL.
Researchers evaluated the efficacy of 100 mg/day of niacin in hemodialysis patients.
The phosphate binder is a useful treatment for hyperphosphatemia with a relatively low pill burden, researchers say.
Patients may need no more than routine evaluation of iron.
Phosphorus targets in patients with chronic kidney disease stage 3 to 4 should be below 4.3 mg/dL, researchers report.
Hyperphosphatemia is present in many who say following diets and binder schedules is easy.
Autonomy support could be an appropriate target for culturally informed strategies to optimize mineral bone health.
A mortality rate increase of 43 cases per 1000 patients was found for calcium-based phosphate binders.
Phosphorus levels are higher when blood specimens are collected after weekends.
Paricalcitol-based protocol includes limited use of calcium-based phosphate binders.
The control of phosphorus is underappreciated, for example.
Average 6-month serum phosphorus level was significantly lower in CKD patients who received niacin than those who did not (3.4 vs. 4.2 mg/dL).
Researchers observe an 81% increase in dialysis patients achieving recommended phosphorus levels after switching to sucroferric oxyhydroxide.
Small case series also confirmed that the diagnosis of calciphylaxis is rarely made in the nodular, non-ulcerative phase.
Renal and Urology News Articles
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)